| Literature DB >> 23896688 |
Abstract
It has now been almost 20 years since the discovery of p38 MAP kinase and its role in inflammatory cytokine synthesis through reverse pharmacology and its subsequent exploration as a potential target for autoimmune and other diseases. At the time of its discovery, the use of cell-based phenotypic screens to identify new molecular targets was at its infancy, and while p38 MAP kinase was not the first target to be identified this way, it provides a useful model for reviewing the pros and cons of this approach and the subsequent impact it can have on discovering new medicines.Entities:
Keywords: drug discovery; p38 MAPK; phenotypic assay; protein kinases; reverse pharmacology
Mesh:
Substances:
Year: 2013 PMID: 23896688 DOI: 10.1177/1087057113497401
Source DB: PubMed Journal: J Biomol Screen ISSN: 1087-0571